Analysis of the primary endpoint showed that treatment with AMG @ at @mg ( Cohort @ ) and @mg ( Cohort @ ) for up to @ weeks resulted in mean @ % and @ % reductions from baseline in PTH during the efficacy assessment phase , respectively ( p < @ for both cohorts compared to placebo group within the cohort ) .